Navigation Links
Long-Term Safety and Efficacy Data on Promacta(TM) (Eltrombopag) Presented at American Society of Hematology Annual Meeting
Date:12/10/2007

Preliminary results demonstrate patients with chronic idiopathic thrombocytopenic purpura increased and maintained platelet counts at greater than or equal to 50,000/microliters with extended treatment

ATLANTA, Dec. 10 /PRNewswire-USNewswire/ -- GlaxoSmithKline today announced data on the long-term safety and efficacy of its investigational drug PROMACTA(TM) (eltrombopag) for the treatment of chronic idiopathic thrombocytopenic purpura (ITP).(1) These preliminary results from the EXTEND (Eltrombopag eXTENded Dosing) study showed that of the patients with a baseline platelet count of less than 30,000/microliters, 73% achieved a platelet count of greater than or equal to 50,000/microliters. The average treatment period for all patients, from this ongoing treatment study, has lasted almost 22 weeks (five months) so far. These results suggest that PROMACTA sustains increased platelet counts during long-term treatment.(1) This research was presented at the 49th Annual Meeting of the American Society of Hematology, December 8-11 2007 in Atlanta, GA.

PROMACTA is an investigational compound that has not received regulatory approval in any market for any indication at this time.

PROMACTA was generally well tolerated in this study. Of the 94 patients who received at least one dose of PROMACTA, 83% reported at least one adverse event (AE), 32% reported a drug-related AE and 13% reported a serious AE (SAE). Most AEs were mild in severity with the most common being headache (20%).(1)

Chronic ITP is a disorder characterized by low levels of platelets in the blood, with patients suffering from excessive bruising and bleeding and in some cases having serious hemorrhages that can be fatal.(2,3,4) An estimated 200,000 individuals are diagnosed with ITP in the U.S.(5) and a similar number in Europe. PROMACTA is an investigational oral, non-peptide, platelet growth factor that induces the proliferation and differentiation of cells in the bone
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
2. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
3. Sexual Function Affected by Stem Cell Transplant According to Long-Term Study
4. Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinsons Disease
5. Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
6. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
7. Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)
8. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
9. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
10. Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus
11. Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA(R) (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... 1, 2015 The breakthrough hepatitis C treatment, ... but manufacturer Gilead Sciences overcame initial market resistance through ... public relations campaigns. Sovaldi,s high cure rate, ... effects propelled the drug to $2.3 billion in sales ... quarter on the market. But Sovaldi,s price tag of ...
(Date:5/1/2015)... Calif. , May 1, 2015 Hitachi ... the United States launch of the ExoComplete™ ... fast and easy system for exosome collection to mRNA ... for Extracellular Vesicles ("ISEV") Annual Meeting, April 23 – ... Both products are intended for research use only of ...
(Date:5/1/2015)... , May 01, 2015 Research and Markets ... "Asian Dermatology Devices Market by Type, by End User ... The Asian Dermatology Devices market is estimated to grow ... China holds a larger share in the ... Japan . The Asian Dermatology Devices market holds ...
Breaking Medicine Technology:New Study Examines Success Lessons of Sovaldi's and Harvoni's Blockbuster Launches 2New Products for Exosome Isolation to mRNA Purification 2Asian Dermatology Devices (Treatment & Diagnostic) Market by Type, by End User - Forecast to 2019 2Asian Dermatology Devices (Treatment & Diagnostic) Market by Type, by End User - Forecast to 2019 3
... , WAYNE, N.J. and EMERYVILLE, Calif., Dec. 11 ... (Nasdaq: ONXX ) today announced results from ... trials were presented at the 32nd Annual San ... these studies evaluated Nexavar® (sorafenib) tablets in combination ...
... , , , LONDON and ... women with an aggressive form of breast cancer experienced a ... combination of TYKERB® (lapatinib) plus HERCEPTIN® (trastuzumab). The results of ... presented during the 32nd Annual CTRC-AACR San Antonio Breast Cancer ...
Cached Medicine Technology:Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 2Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 3Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 4Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 5Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 6Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 7GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 2GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 3GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 4GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 5GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 6
(Date:5/3/2015)... VEGAS and LOS ANGELES, American Telemedicine Association 2015 ... vitaphone e-health solutions, a full-service telemedicine ... launch of its new platform, VITA health services ... The VITA health services platform enables remote patient ... such as congestive heart failure (CHF), diabetes, COPD, ...
(Date:5/3/2015)... 03, 2015 “ BolehVPN ” was featured ... features the latest and coolest technology products available to consumers. ... conducted the review and shared with viewers how to protect ... these days is on computers and even more so online. ... meet people all over the world. In terms of work, ...
(Date:5/3/2015)... Hanover, MA (PRWEB) May 03, 2015 It is ... 3rd Annual Brain Aneurysm Walk in Memory of Lissa Anne Been ... of Lissa organized this great family-friendly event to honor her loving ... since its inception. , Just having turned 37, Lissa suffered ... Lissa passed away on August 24, 2012. This event is designed ...
(Date:5/2/2015)... 2015 Vancouver fencing company, QS Fencing, has ... advice to prospective clients related to their questions on railings ... railings around their decks and patios. While that seems like ... up once the person rolls up their sleeve to start ... railing in finding a gate that matches it. , Instead ...
(Date:5/2/2015)... 2015 We are pleased to announce ... Center as one of the Top Workplaces of 2015. ... addiction treatment field for their ethics and standards of ... to continue their educational efforts. The Delray Recovery Center ... forgetting their purpose – to help individuals heal from ...
Breaking Medicine News(10 mins):Health News:vitaphone e-health solutions U.S. Announces VITA Health Services for Remote Chronic Disease Management 2Health News:vitaphone e-health solutions U.S. Announces VITA Health Services for Remote Chronic Disease Management 3Health News:A Method to Keep Private Information Secure was Featured on NewsWatch Television 2Health News:Renowned Brain Aneurysm Foundation to Benefit from Arnold, Missouri’s 3rd Annual Brain Aneurysm Walk in Memory of Lissa Anne Been 2Health News:Professional Staff at QS Fencing Company Now Provides Advice on Railings and Gates 2Health News:The Delray Recovery Center Named 2015 Top Workplace 2
... rise in childhood obesity being blamed on the beverage ... substitute their sugary soft drinks// with low-calorie ... for a Healthier Generation. a joint initiative of the ... negotiated the plan with Cadbury Schweppes, Coca-Cola and PepsiCo ...
... have genetically modified mice in a study that would ... ,The research team was from the University of Texas ... results of the research were published in the journal Neuron. ... Pten in these mice.This gene has been known to be ...
... diagnostic tests for micro vascular cardiac disease on the lines ... be a good boost// to the researchers to develop novel ... afflict women much more than men. ,“Only in ... - a dysfunction of the heart’s small arteries - as ...
... food choices can play a crucial role in determining ... study // conducted by researchers at Boston University School ... The impact of this problem is more relevant in ... and healthy food is inadequate. ,‘What we ...
... competence of medical staff in the operating room, has ... and increased awareness regarding operating room safety. // Surprisingly, ... to teamwork. ,The survey, called the Safety ... questionnaire and applied to the health care environment. The ...
... sclerosis patients harbor immune cells that specifically overreact to ... mononucleosis. Although EBV has been suspected to play a ... had been largely unknown. ,Scientists think that ... with coordination and balance—is a result of the immune ...
Cached Medicine News:Health News:Nutritious Beverages to be Sold in School 2Health News:Micro vascular Disease Enabled with a Superior Test, Courtesy: Women’s Heart Progra 2Health News:Nurses Outsmart Surgeons When It Comes Safety And Team Wok 2Health News:Nurses Outsmart Surgeons When It Comes Safety And Team Wok 3Health News:EBV Might Trigger Multiple Sclerosis, Study 2Health News:EBV Might Trigger Multiple Sclerosis, Study 3Health News:EBV Might Trigger Multiple Sclerosis, Study 4
Shandon Laser MicroWriter is a laser labeling system developed specifically for anatomical pathology....
Eberbach's 2800 Series Micro Slide Cabinets provide safe, short-term and long-term, storage of prepared slides which can easily be indexed for retrieval. Cabinets are available in (2) two styles, a U...
Compact storage cabinets for 35 mm slides....
Fisherbrand* Micro Slide Cabinet is made of heavy gauge, reinforced steel....
Medicine Products: